Clinical and regulatory intelligence for Complement-Mediated Kidney Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

ADX-038 →

Relevant companies

No related entities indexed yet.

Recent signals(1)

ClinicalAugust 8, 2026

Phase 2 Study of ADX-038 Targets Complement-Mediated Kidney Disease

A Phase 2 study is underway to evaluate ADX-038 for safety and efficacy in adults with complement-mediated kidney diseases.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Complement-Mediated Kidney Disease →

Nephrology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.